On August 24, Jincheng Pharm, a listed company on the Shenzhen Stock Exchange, stated on an investor Q&A platform that they have the capability to export their synthesized nicotine and possess the necessary qualifications for export. The nicotine project has a production capacity of 200 tons per year and is currently undergoing technical upgrades.
In addition, the company also expressed strong optimism about the e-cigarette industry. On one hand, the company plans to expand its nicotine industry horizontally by utilizing its nicotine extraction platform and expanding its spice products. On the other hand, the company will actively seek opportunities to expand downstream, fully leveraging the value advantages of its upstream nicotine industry to become a leading player in the nicotine industry. Furthermore, in 2023, the company's wholly-owned subsidiary, Jincheng Pharmaceuticals, obtained new export qualifications for nicotine used in e-cigarettes, and its production scale has been further expanded. This development is significant as it allows the company to expand its domestic and international markets and serve downstream customers.
At the same time, when asked if they supply goods to Skoal, the company stated that its clients are downstream e-cigarette liquid businesses, not Skoal, which is not an e-liquid manufacturer.
This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.
